Products

Browse our products

Want to know more?
Reach out to our team to know more about the product or how to purchase
 
Get more information

Streck CD-Chex TdT Plus®

CD-Chex TdT Plus is the only commercially available flow cytometry control that includes TdT, CD1a, CD34 and cCD3 in a single control.

It is a positive procedural control that provides reference values for abnormal cells often found in certain types of hematopoietic neoplasms.

CD-Chex TdT Plus is a ready-to-use control for evaluating intracellular and surface antigens including CD1a, CD2, CD4, CD5, CD7, CD8, CD34, cytoplasmic CD3 and nuclear TdT, with monoclonal antibody binding by flow cytometry. When the cells are stained with fluorescent antibodies and analyzed by flow cytometry, CD Chex TdT Plus provides reference values for abnormal peripheral blood leukocytes often found in certain types of hematopoietic neoplasms.

It is a positive procedural control designed to monitor reagent staining, erythrocyte lysis, sample preparation and instrument performance. CD-Chex TdT Plus is compatible with BD Biosciences and Beckman Coulter flow cytometry systems.

Features

  • Only flow cytometry control assayed for TdT, CD1a, CD34 and cytoplasmic CD3
  • Other assayed markers include CD2, CD4, CD5, CD7 and CD8
  • Offers a high level of CD34: over 60% positive for CD34+ (abnormal)
  • Compatible with BD Biosciences and Beckman Coulter flow cytometry systems
  • 30-day open-vial stability
  • 90-day closed-vial stability
     

Benefits

  • Helps toward meeting quality requirements for leukemia and lymphoma immunophenotyping
  • Helps technologists to identify and gate assayed markers
  • Established assay ranges provide less room for error
  • Reduces the need for labs to hold and validate patient samples for use as a control
  • Access to STATS®, a free interlaboratory quality control program with peer group data comparison and online submission

For more information, visit Streck.com.

Related Products

    Receive our newsletter to get the latest news about our products and services

    * indicates required

    By signing up to our newsletter, you agree to our Data Privacy Policy.